UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029624
Receipt number R000033838
Scientific Title The study regarding screening tests for HIV complications associated with aging in HIV infected patients.
Date of disclosure of the study information 2017/12/01
Last modified on 2018/04/27 10:30:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study regarding screening tests for HIV complications associated with aging in HIV infected patients.

Acronym

HIV aging study

Scientific Title

The study regarding screening tests for HIV complications associated with aging in HIV infected patients.

Scientific Title:Acronym

HIV aging study

Region

Japan


Condition

Condition

HIV infection

Classification by specialty

Infectious disease

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To find out the possibility of early detection of malignant tumors associated with aging in HIV infected patients through performing FDG-PET/CT examinations and tumor marker test.

Basic objectives2

Others

Basic objectives -Others

Epidemiology

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Presence of undiagnosed malignant tumor in HIV positive patients with hemophilia

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Starting from December 2017 to the end of December 2020, we will conduct at least one malignant tumor screening tests, including FDG-PET/CT and blood tumor marker test.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

35 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) HIV infected patients with hemophilia who are 35 years old or older or
2) HIV litigation plaintiffs resident in Tokai block
and
3) Consent to participant has been obtained in a written form.

Key exclusion criteria

1) If an attending physician decides the patient requires urgent treatment
2)A patient with poor control of diabetes (FBS>150mg/dL)
3) A patient with serious underlying disease, which may lead to liver/kidney dysfunction and/or metabolic disorder
4) A patient with mental illness or psychiatric symptoms determined to confront difficulty when participating in the study
5)A patient with history of hypersensitivity to FDG
6) Other patients, whose attending physician has determined inappropriate to participant

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshiyuki Yokomaku

Organization

National Hospital Organization Nagoya Medical Center

Division name

Department of AIDS clinic

Zip code


Address

4-1-1 Sannnomaru, Naka-ku, Nagoya, Aichi, Japan

TEL

052-951-1111

Email

yokomaku@nnh.hosp.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yoshiyuki Yokomaku

Organization

National Hospital Organization Nagoya Medical Center

Division name

Department of AIDS clinic

Zip code


Address

4-1-1 Sannnomaru, Naka-ku, Nagoya, Aichi, Japan

TEL

052-951-1111

Homepage URL


Email

yokomaku@nnh.hosp.go.jp


Sponsor or person

Institute

National Hospital Organization Nagoya Medical Center

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

名古屋医療センター(愛知県)


Other administrative information

Date of disclosure of the study information

2017 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2017 Year 11 Month 30 Day

Date of IRB


Anticipated trial start date

2017 Year 12 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 10 Month 19 Day

Last modified on

2018 Year 04 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033838


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name